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Abstract: The present study was conducted to find out the predictors of side effects such as 
nausea and excessive sweating induced by milnacipran, a serotonin/norepinephrine reuptake 
inhibitor. Both clinical characteristics prior to the treatment and gene polymorphisms such as 
serotonin transporter (5-HTT) gene-linked polymorphic region (5-HTTLPR), a variable number 
of tandem repeats in the second intron of the 5-HTT gene (5-HTTVNTR), 5-HT2A receptor 
gene (5-HT2A G-1438A), a TPH gene polymorphism in intron 7 (TPH A218C), norepinephrine 
transporter (NET) gene polymorphism in the promoter region (NET T-182C) and in the exon 
9 (NET G1287A), a variable number of tandem repeats in the promoter region of monoamine 
oxidase A, were items to be assessed in this study. Ninety-six patients with major depressive 
disorder were treated with milnacipran. Side effects were assessed at 1, 2, 4, and 6 weeks of 
treatment with Udvalg for Kliniske Undersogelser side effects scale. The results showed that no 
gene polymorphisms included in this study affected the susceptibility of nausea and excessive 
sweating induced by milnacipran. Patients with older age are more likely to develop excessive 
sweating than others. The major limitation of this study is a small sample size. Further studies 
with larger populations and more kinds of gene polymorphisms should be needed to see if specific 
gene polymorphisms determine the susceptibility of side effects induced by milnacipran.
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Introduction
Adverse events are common even in the newer antidepressant drugs, such as selective 
serotonin reuptake inhibitors (SSRIs) and dual serotonin/norepinephrine reuptake 
inhibitors (SNRIs), which have been reported to possess higher tolerance compared to 
tricyclic antidepressants (TCAs).1,2 Adverse events of antidepressants have been reported 
to be the most common reasons for poor adherence to antidepressant therapy, resulting 
in high relapse rates.3 Thus careful attention should be paid to adverse events not only 
in the early phase of the treatment but also during maintenance after remission.
Knowledge of predictive factors can help to minimize the incidence of adverse 
events with antidepressants. Certain gene polymorphisms related to serotonin neuro-
transmission appear to be predictive of sensitivity to the adverse events of SSRI 
antidepressants.4–6 To our knowledge, however, there are no reports investigating the 
predictive factors for adverse events induced by SNRI antidepressants such as venla-
faxine, milnacipran, or duloxetine. In this study, we examined the possible association 
between adverse events induced by the SNRI, milnacipran, and gene polymorphisms 
related to serotonergic or noradrenergic neurotransmission. We focused on seven 
polymorphisms: 1) the serotonin transporter (5-HTT) gene-linked polymorphic region Neuropsychiatric Disease and Treatment 2009:5 394
Higuchi et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
(5-HTTLPR); 2) the variable number of tandem repeats 
in the second intron of the 5-HTT gene (5-HTTVNTR); 
3) the 5-HT2A receptor gene (5-HT2A G-1438A); 4) the 
tryptophan hydroxylase (TPH) gene polymorphism in 
intron 7 (TPH A218C); 5) the norepinephrine transporter 
(NET) gene polymorphism in the promoter region (NET 
T-182C) and 6) in the exon 9 (NET G1287A); and 7) the 
variable number of tandem repeats in the promoter region 
of monoamine oxidase A (MAOA-VNTR). The aim of this 
study is to investigate whether polymorphisms of specific 
genes affect the occurrence of adverse events induced by 
the SNRI, milnacipran.
Methods
subjects and treatment
Patients meeting the DSM-IV diagnosis of major depressive 
disorder and who scored 20 or more on the Montgomery and 
Asberg Depression Rating Scale (MADRS)7 were included in 
this study. Patients with other Axis I disorders or with Axis II 
disorders were excluded by clinical assessment based on The 
Mini-International Neuropsychiatric Interview. The patients 
were 20–69 years of age and free of psychotropic drugs for 
at least 14 days before entry into the study. Milnacipran was 
administered twice daily (the same dose after dinner and at 
bedtime) for six weeks. We have two reasons for our choice 
of administration time. One reason is that the elimination 
half-life of milnacipran is not long. Therefore, we need to 
give it to the patients separately. Another reason is that the 
daytime medication has to be omitted for the accurate assess-
ment of steady-state plasma milnacipran concentration. The 
initial total daily dose was 50 mg/day and after one week it 
was increased to 100 mg/day, which is the recommended 
dose in Japan.8,9 Patients with insomnia were prescribed 
brotizolam (0.25 or 0.5 mg), a benzodiazepine sedative 
hypnotic. No other psychotropic drugs were permitted dur-
ing the study.
Assessment
Adverse events were assessed using the Udvalg for Kliniske 
Undersogelser (UKU) side effects scale, which developed 
to provide a comprehensive side effect rating scale with 
well-defined and operationalized items to assess the side 
effects of psychopharmacological medications.10 Depression 
symptom severity was assessed using the MADRS and a 
clinical response was defined as a 50% or greater decrease 
from baseline at the endpoint (or at the time when patients 
withdraw from the study in the case of early termination). 
The assessments of adverse events and treatment response 
were conducted at baseline and 1, 2, 4, and 6 weeks after 
initiation of milnacipran. A single rater conducted all ratings 
for each patient. If patients had certain “adverse event-like” 
symptoms before the start of the milnacipran treatment, these 
symptoms were not subsequently counted as adverse events. 
Because patients with major depression often complain of 
somatic symptoms, very mild symptoms of which total UKU 
scale change was equal to or less than 1 over the whole study 
period were excluded for adverse event profile.
Blood samples for quantification 
of plasma milnacipran concentration 
and genotyping
Blood samples were collected 12 hours after drug adminis-
tration at bedtime, four weeks after initiation of milnacipran 
treatment, for both genotyping and measurement of plasma 
milnacipran concentration. Details of the analytical method 
have been described previously.11 Genotyping was performed 
for the polymorphisms described below.
5-HTT gene-linked polymorphism (5-HTTLPR), a 
variable number of tandem repeats in the second intron of the 
5-HTT gene (5-HTTVNTR), a G-1438A polymorphism in 
the promoter region of the 5-HT2A receptor gene (5-HT2A 
G-1438A) and a TPH gene polymorphism in intron 7 (TPH 
A218C) were determined as described previously.12–15
Both of the NET gene polymorphisms in the promoter 
region (T-182C) and in the exon 9 (G1287A) were deter-
mined as described by Jonsson and colleagues.16
A variable number of tandem repeats in the promoter 
region of MAOA gene (MAOA-VNTR) was determined by 
Yoshida and colleagues.6
Statistical analysis
Differences in clinical characteristics between subjects with 
and without nausea, or between subjects with and without 
sweating were analyzed with the use of the unpaired t-test 
or chi-square test where appropriate. Plasma milnacipran 
concentrations were also analyzed with the use of unpaired 
t-test. A p value lower than 0.05 was considered to be statisti-
cally significant in the above analysis.
Genotype distributions of each polymorphisms in patients 
with and without side effects were analyzed with the use of 
the chi-square test and Bonferroni corrections applied for 
multiple testing. The Bonferroni procedure uses a powerful 
family-wise error-rate controlling. However, the power to 
detect a specific hypothesis is reduced when the number of 
hypotheses in the family increases. Therefore, in our asso-
ciation analysis here, overall statistical significant level was Neuropsychiatric Disease and Treatment 2009:5 395
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set to 0.1. Hence, the family-wise error-rate after Bonferroni 
corrections was 0.007 (0.1/14). We excluded MAOA VNTR 
group from the statistical analysis because of violation of 
Hardy–Weinberg equilibrium.
The Ethics Committee of Akita University School of 
Medicine approved this study. All subjects received a full 
explanation of the study and only those who gave written 
consent to participate were enrolled in the study.
Results
Characteristics of patients
Ninety-six patients were initially recruited. Of these 
16 patients were excluded from the study for the following 
reasons; one patient withdrew from the study because of 
acute deterioration of depressive symptoms, four patients 
stopped visiting our hospital without explanation, six patients 
were considered to have poor compliance, showing very low 
milnacipran concentrations, and five patients refused genetic 
sampling. No patients withdrew from the study due to side 
effects. A total of 80 patients: 52 women and 28 men, 49 out-
patients and 31 inpatients, aged 25–69 years (mean age ± 
SD = 52.4 ± 14.3), were included in the statistical analysis.
Adverse events and treatment response 
induced by milnacipran
Table 1 shows the incidence of side effects in this study. Of 
80 patients, 30 (37.5%) developed adverse events. Of those 
30 patients, 20 had only a single side effect while the remaining 
10 experienced two or more different adverse events.
Mean MADRS scores dropped significantly from 28.6 ± 
5.4 (mean ± SD) to 12.4 ± 9.1 (mean ± SD) during the study 
period (p  0.05). Fifty out of 80 patients (62.5%) were consi-
dered as responders at the end of the study. No significant 
associations were found between treatment response and 
incidence of any adverse effects (data not shown).
Predictive factors of side effects
We focused on nausea and sweating, which were two 
principal adverse events, developing in more than 10% of 
patients taking milnacipran in this study. Only one patient 
developed both nausea and sweating.
Nausea
Table 2 shows the clinical characteristics in patients with 
and without nausea. No clinical characteristics at baseline 
affected the development of nausea induced by milnacipran. 
Plasma milnacipran concentrations in patients with and with-
out nausea were similar (90.7 ± 39.2 ng/ml and 91.8 ng/ml, 
respectively). Table 3 shows genotype distributions in 
patients with and without nausea. There were no significant 
differences in genotype distributions of any polymorphism 
between patients with and without nausea.
excessive sweating
Table 4 shows clinical characteristics in patients with and 
without excessive sweating. There was a statistical signifi-
cant difference (p = 0.03) in the mean age of the two groups 
(patients with sweating: 59.6 ± 7.9 years; patients with no 
sweating: 50.3 ± 12.3 years). No other clinical characteristics 
differed significantly between the two groups. Mean plasma 
concentrations of milnacipran were similar (89.4 ± 40.3 ng/ml 
and 93.1 ± 37.3 ng/ml in patients with and without excessive 
sweating, respectively). Table 5 shows that no significant 
Table 1 Adverse events induced by milnacipran treatment (N = 80)
  Number of patients (%)
Nausea 10 12.5
increased sweating 10 12.5
Headache 7 8.8
constipation 5 6.3
Palpitation 4 5.0
Dry mouth 3 3.8
Discomfort of head 3 3.8
Chill or heat of leg or arms 3 3.8
sleep disturbance 2 2.5
Bitterness 1 1.3
Inner tension/anxiety 1 1.3
Blurred vision 1 1.3
stomach ache 1 1.3
Urinary hesitancy 1 1.3
Tremor 1 1.3
Diarrhea 1 1.3
skin tingling 1 1.3
Table 2 Clinical characteristic of patients with and without 
nausea (N = 80)
Nausea (+)
(N = 10)
Nausea (-)
(N = 70)
p value
Sex (male/female) 5/5 25/49 p = 0.31
Age (year)a 53.4 ± 14.7 51.1 ± 11.9 p = 0.59
Number of previous episodesa 0.1 ± 0.3 0.4 ± 1.1 p = 0.42
Melancholia (±) 2/8 22/48 p = 0.71
MADRs score at baseline 28.4 ± 5.4 28.6 ± 6.2 p = 0.61
Notes: aData are expressed as mean ± SD.   A p value lower than 0.05 is defined as 
statistically significant.Neuropsychiatric Disease and Treatment 2009:5 396
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differences were found in genotype distributions of each 
polymorphism between patients with and without exces-
sive sweating. No significant differences were also found 
on age among each genotype in each polymorphism (data 
not shown).
Discussion
A major limitation of this study is the small number of 
patients for genetic study. This limitation drastically 
decreases the power and therefore increases the possibility 
of a false positive finding. More patients should have been 
assessed to increase the accuracy of the study results. To our 
knowledge, however, this is the first study aimed to find out 
the predictor of side effects induced by an SNRI. We think 
the results of this study are worth reporting.
The present study indicated that no association was 
found between gene polymorphisms assessed in this study 
and milnacipran-induced side effects such as nausea and 
excessive sweating. Each adverse event is reported to be 
associated mainly with stimulation of serotonergic and 
noradrenergic neurotransmission, respectively. Some 
researchers including ourselves have reported the possible 
interactions between serotonergic gene polymorphisms and 
incidence of SSRI-induced nausea.4–6 However, we did not 
find any serotonergic gene polymorphisms that were related 
to milnacipran-induced nausea. These differences in the 
results may come from the differences in pharmacological 
profiles between SSRI and SNRI. Exact mechanism of this 
difference, however, is unknown.
Excessive sweating is a common adverse effect of many 
antidepressant medications. The rates of this incidence 
have been reported in 10% of patients taking SSRIs, 14% 
of patients taking TCAs and 12%–14% of patients taking 
the SNRI, venlafaxine, which are in accordance with the 
rate of 11.8% in this study.17–20 Some reports indicated that 
noradrenalin is involved with the mechanisms of excessive 
sweating induced by antidepressants.21,22 Therefore, there is 
a possibility that gene polymorphisms related to noradrena-
lin neurotransmitter function have some association with 
excessive sweating induced by milnacipran. So far, no report 
described the relationship between antidepressant-induced 
sweating and gene polymorphisms. Although our study is 
the first report in this field, the results could not detect any 
association between noradrenergic gene polymorphisms and 
milnacipran-induced excessive sweating. In order to increase 
the chance to find out the specific genes related to this side 
effect, a larger sample size and more different kinds of gene 
polymorphisms are need to be analyzed.
The data also showed that patients in older age had higher 
susceptibility to milnacipran-induced excessive sweating. 
This finding suggests that caution should be taken to avoid 
Table 3 genotype distributions in patients with and without nausea 
(N = 80)
Group Genotype distribution (N) p value
5-HTT LPR 
 
Nausea (+) 
Nausea (-)
 
S/S 
5 
46
 
S/L 
4 
23
 
L/L 
0 
2
 
 
χ2 = 0.70 
p = 0.70
5-HTT   VNTR 
 
Nausea (+) 
Nausea (-)
 
12/12 
7 
58
 
12/10 
2 
11
 
10/10 
0 
2
 
 
χ2 = 0.49 
p = 0.78
5-HT2A g-1438A  
 
Nausea (+) 
Nausea (-)
 
A/A 
2 
22
 
G/A 
5 
31
 
G/G 
2 
18
 
 
χ2 = 0.48 
p = 0.78
MAOA   VNTR  
 
Nausea (+) 
Nausea (-)
 
1/1 
7 
35
 
1/3 
0 
17
 
3/3 
2 
17
 
 
(-) 
(-)
TPH A218c 
 
Nausea (+) 
Nausea (-)
 
A/A 
2 
19
 
A/C 
6 
32
 
C/C 
1 
20
 
 
χ2 = 1.7 
p = 0.42
NeT T-182c  
 
Nausea (+) 
Nausea (-)
 
T/T 
3 
27
 
T/C 
5 
40
 
C/C 
1 
4
 
 
χ2 = 0.43 
p = 0.80
NeT g1287A 
 
Nausea (+) 
Nausea (-)
 
G/G 
6 
32
 
G/A 
3 
32
 
A/A 
0 
7
 
 
χ2 = 1.9 
p = 0.38
Notes: MAOA VNTR was excluded from analysis because of violation of Hardy–
Weinberg equilibrium.    A p value lower than 0.007 is defined as statistically significant 
(see text for detail).
Table 4 Clinical characteristics of the patients with and without 
sweating (N = 80)
   Sweating (+) 
(N = 10)
Sweating (-) 
(N = 70)
p value 
Sex (male/female) 4/6 24/46 p = 0.73
Age (year)a 59.6 ± 7.9 50.3 ± 12.3 *p = 0.03
Number of previous 
episodesa
0.33 ± 0.71 0.39 ± 1.11 p = 0.87
Melancholia (+/-) 3/7 21/49 p . 0.99
MADRs score 
at baseline
27.3 ± 5.8  28.8 ± 6.1  p = 0.75 
Notes: aData are expressed as mean ± SD. *A p value lower than 0.05 is defined as 
statistically significant.Neuropsychiatric Disease and Treatment 2009:5 397
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this side effect when prescribing milnacipran in patients 
with older age. The underlying reason why older patients 
are susceptible to this side effect is unknown.
Morishita and colleagues23 suggested that in patients who 
were aged 50 or older, milnacipran had a tendency to be 
more effective than fluvoxamine and paroxetine. Age may 
be associated not only with treatment response but also the 
side effects of milnacipran.
The findings from this study should be taken as prelimi-
nary. Information from more kind of gene polymorphisms 
with larger population are needed to see if specific gene 
polymorphisms determine the susceptibility of side effects 
induced by milnacipran.
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